TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

Scientists say myeloid-derived suppressor cells (MDSCs) engineered with human induced pluripotent stem cells (iPSC) may hold the key to migrating off-the-shelf MDSCs to the clinical setting, where...

Tumor-specific antigens remain elusive in T-cell lymphomas (TCL), effectively limiting the impact of chimeric antigen receptor (CAR) T-cell therapy in this setting, but scientists are encouraged...

Researchers report favorably on the use of combined post-transplant cyclophosphamide (PTCy) and abatacept as prevention against graft-versus-host disease (GVHD) after allogeneic transplantation...

Conventional conditioning methods ahead of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can lead to tissue damage and systemic toxicities in patients with Fanconi anemia (FA),...

Programmed cell death 1 (PD-1) ligands may be part of the challenge in applying chimeric antigen receptor (CAR) T-cell therapy to solid tumors but, researchers suspect, they also could be part of...

Study results indicate that cell therapy using B7 homolog 3 (B7-H3/CD276) may be a promising pathway in the pursuit of targeted therapies to treat ependymomas (EPNs).